PiaSky (crovalimab), which can be self-administered by patients following adequate training, will be available on the NHS in England and Wales as a monotherapy for eligible adults and adolescents aged 12 years and older and weighing at least 40kg.
Affecting approximately 1.59 per every 100,000 people in the UK, PNH occurs when the red blood cells are destroyed by the complement system. This results in symptoms such as anaemia, fatigue, blood clots, and can lead to kidney disease.
Current C5 inhibitors, including AstraZeneca’s Soliris (eculizumab) and Ultomiris (ravulizumab), block part of the complement system cascade and can be effective in treating the condition, but require regular intravenous infusions…
